LifeTime will profoundly expand our basic understanding of the genome and cell by generating a wealth of new tools and technologies to measure, analyse and predict cellular mechanisms and functions.

LifeTime is expected to fundamentally impact basic science across multiple fields including developmental biology, regeneration, stem cell biology, RNA biology, epigenetics, signalling, cancer biology, neurobiology and metabolism. It will redefine the role of machine learning in basic science and precision medicine, which will be based on cellular biology and artificial intelligence.

The synthesis of 21st century biology and data sciences will impact medical practice and improve human health, reducing the economic burden of aging populations.

LifeTime will stimulate new developments in the healthcare sector, providing benefits to the EU economy in terms of business volume, jobs, and personal income for European households. The pharmaceutical industry in Europe will be strengthened by the general acceptance of targeted medicines. The implementation of innovative technologies in toxicology studies and improved patient stratification in clinical trials will lead to substantial savings in the cost of drug development. High-tech industries and the emerging AI sector will be boosted by the development of knowledge and technology that go far beyond the state-of-the-art in linking molecular analysis at single-cell resolution to early detection and interception of diseases, thus making Europe a leader in this key driver of future economic growth. European SMEs that develop instruments, software and systems for clinical-grade molecular sequencing, mass spectrometry, microscopy, image analysis and AI systems will spin off and flourish. Improved early disease detection and interception will enable healthier ageing, leading to substantial savings in healthcare expenses and care costs for the elderly.